Egypt’s EDA explores pharma collaboration with Indian firm

Egyptian Drug Authority (EDA) Chairman Ali El-Ghamrawy discussed potential collaboration with EIPICO and Reliance Life Sciences India to enhance Egypt’s pharmaceutical industry, as per a Cabinet statement on Thursday.

The efforts of both companies in supporting the pharmaceutical sector were praised, especially in the development of pharmaceutical products and promoting innovation, according to the statement.

El-Ghamrawy emphasised the significance of collaboration between domestic and global companies to facilitate the transfer of knowledge and advanced technologies, as stated in the release.

Furthermore, he praised EIPICO for supporting Egypt’s pharmaceutical industry and Reliance Life for its successful pharmaceutical research and global marketing of biosimilars, the statement added.

The EDA is prepared to offer technical and procedural assistance, support partnerships with local entities, and simplify processes for entering and competing in the Egyptian pharmaceutical market.

He praised the Egyptian pharmaceutical market’s strength and regional growth, citing sales of 307 billion Egyptian pounds last year, up from 216 billion pounds in 2023. He mentioned that 3.5 billion packages were traded last year compared to 3.7 billion in 2023.

The meeting aligns with the EDA’s strategy to enhance pharmaceutical policies and strengthen global partnerships, ensuring high-quality, affordable medicines while improving healthcare services for Egyptian citizens.

Attribution: Amwal Al Ghad English

Subediting: M. S. Salama